- Home
- JHI vs OPTN Comparison
JHI vs OPTN Comparison
Compare JHI & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHI
- OPTN
- Stock Information
- Founded
- JHI 1971
- OPTN 2010
- Country
- JHI United States
- OPTN United States
- Employees
- JHI N/A
- OPTN N/A
- Industry
- JHI Trusts Except Educational Religious and Charitable
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- JHI Finance
- OPTN Health Care
- Exchange
- JHI Nasdaq
- OPTN Nasdaq
- Market Cap
- JHI 121.0M
- OPTN 117.6M
- IPO Year
- JHI N/A
- OPTN 2017
- Fundamental
- Price
- JHI $14.36
- OPTN $0.66
- Analyst Decision
- JHI
- OPTN Strong Buy
- Analyst Count
- JHI 0
- OPTN 2
- Target Price
- JHI N/A
- OPTN $4.00
- AVG Volume (30 Days)
- JHI 29.5K
- OPTN 504.8K
- Earning Date
- JHI 01-01-0001
- OPTN 11-07-2024
- Dividend Yield
- JHI 6.80%
- OPTN N/A
- EPS Growth
- JHI N/A
- OPTN N/A
- EPS
- JHI 1.05
- OPTN N/A
- Revenue
- JHI N/A
- OPTN $75,058,000.00
- Revenue This Year
- JHI N/A
- OPTN $24.44
- Revenue Next Year
- JHI N/A
- OPTN $49.00
- P/E Ratio
- JHI $12.47
- OPTN N/A
- Revenue Growth
- JHI N/A
- OPTN 3.91
- 52 Week Low
- JHI $11.63
- OPTN $0.65
- 52 Week High
- JHI $13.40
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- JHI 81.13
- OPTN 30.20
- Support Level
- JHI $13.73
- OPTN $0.65
- Resistance Level
- JHI $14.15
- OPTN $0.74
- Average True Range (ATR)
- JHI 0.10
- OPTN 0.04
- MACD
- JHI 0.03
- OPTN 0.00
- Stochastic Oscillator
- JHI 83.56
- OPTN 22.50
About JHI John Hancock Investors Trust
John Hancock Investors Trust is a United States-based diversified, closed-end management investment company. It seeks to generate income for distribution to its shareholders. The secondary objective of the company is capital appreciation. The portfolio composition of the fund comprises corporate bonds, U.S. government agencies, preferred securities, asset-backed securities, common stocks, short-term investments, and others.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.